Three new peptide-based diabetes drugs (exenatide/GLP-1, sitagliptin/DPP-4, pramlintide/amylin) evaluated from a managed care perspective for cost-effectiveness, positioning, and optimal patient selection.
Key findingManaged care analysis of exenatide (GLP-1 agonist: weight loss, injectable), sitagliptin (DPP-4 inhibitor: oral, weight neutral), and pramlintide (amy
What the researchers found
Managed care analysis of exenatide (GLP-1 agonist: weight loss, injectable), sitagliptin (DPP-4 inhibitor: oral, weight neutral), and pramlintide (amylin analog: injectable, weight loss) for T2DM positioning — incretin drugs transforming diabetes pharmacotherapy economics.
Why it matters
Relevant for glp-1, exenatide, diabetes.
How the study worked
review study.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Managed care perspective on three new agents for type 2 diabetes.
Journal of managed care pharmacy : JMCP, 14(4), 363-80
Citation
VanDeKoppel, Shawna; Choe, Hae Mi; Sweet, Burgunda V. (2008). Managed care perspective on three new agents for type 2 diabetes.. Journal of managed care pharmacy : JMCP, 14(4), 363-80. https://doi.org/10.18553/jmcp.2008.14.4.363